Overview
PEIJIA-B (9996)
Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and ne...
- Open
- 3.830
- High
- 3.920
- Low
- 3.650
- Prev. Close
- 3.830
- Volume
- 772.00K
- Turnover
- 2.88M
- Avg Price
- 3.737
- Bid/Ask Ratio
- 92.59%
- Amplitude
- 7.05%
- 52wk High
- 7.370
- Volume Ratio
- 0.83
- Turnover Ratio
- 0.11%
- 52wk Low
- 3.545
- HK Mkt Cap
- 2.47B
- Market CapHKD
- 2.47B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.240
- EPSDynamic
- -0.0258
- EPSStatic
- --
- BVPS
- 3.13
- P/B
- 1.17
- HK Shares
- 676.96M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 676.96M
- Min lot size
- 1,000
- Currency
- HKD
PEIJIA-B Analyst Rating
View moreForecast & Rating
Aug 27, 2026- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 3
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Jul, 3
Peijia Medical (9996.HK) opened low and rallied today, climbing from yesterday's close of HKD 4.100 to an intraday high of HKD 4.380 in the morning session before pulling back to close at HKD 4.320, up 5.37% from the previous close and breaking a recent downtrend. The rally was primarily driven by the company receiving NMPA approval for its TaurusTrio transcatheter aortic valve system, the first interventional treatment in China for aortic regurgitation, which sparked a revaluation of its product pipeline. Financially, operating revenue grew 19.57% YoY in Q4 2025 and 12.81% in Q3 2025, while net losses narrowed by over 10% in both quarters, pointing to gradual fundamental improvement. However, the current price of HKD 4.320 remains more than 53% below the 52-week high of HKD 9.36 and sits below the 60-day moving average of HKD 5.362, indicating a still-weak price position; the stock is down 29.41% year-to-date. Intraday turnover was light at only 673,000 shares, suggesting the rebound's sustainability requires further volume confirmation.
News
Market Movers · Peijia climbs 6% in Hong Kong trading
Market Movers · PEIJIA hits 52-week low
Global Report · Robotics Momentum Builds as Hong Kong's Niche Innovators Diverge
Global Report · Cardiovascular Innovators Outpace Traditional Drugmakers in Hong Kong Healthcare Shift
Global Report · Hong Kong's Forgotten Small Caps Are Splitting in Two
